Evidence map›Paper›PMID 25904892›Full record

ArticleFrontiers in neurology2015

Potassium channel activator attenuates salicylate-induced cochlear hearing loss potentially ameliorating tinnitus.

Wei Sun, Jun Liu, Chao Zhang, Na Zhou, Senthilvelan Manohar, Wendy Winchester, Jason A Miranda, Richard J Salvi

Open access · goldAbstract read
In one paragraph

Article in Frontiers in neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Wei SunCenter for Hearing and Deafness, State University of New York at Buffalo , Buffalo, NY , USA.
Jun LiuDepartment of Otolaryngology, General Hospital of PLA , Beijing , China.
Chao ZhangDepartment of Otolaryngology, General Hospital of PLA , Beijing , China.
Na ZhouDepartment of Otolaryngology, Peking University Third Hospital , Beijing , China.
Senthilvelan ManoharCenter for Hearing and Deafness, State University of New York at Buffalo , Buffalo, NY , USA.
Wendy WinchesterNeusentis Research Unit, Pfizer , Cambridge , UK.
Jason A MirandaNeusentis Research Unit, Pfizer , Cambridge , UK.
Richard J SalviCenter for Hearing and Deafness, State University of New York at Buffalo , Buffalo, NY , USA.
University at Buffalo, State University of New York · USChinese PLA General Hospital · CNPfizer (United Kingdom) · GBPeking University Third Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High dose sodium salicylate causes moderate, reversible hearing loss and tinnitus. Salicylate-induced hearing loss is believed to arise from a reduction in the electromotile response of outer hair cells (OHCs) and/or reduction of KCNQ4 potassium currents in OHCs, which decreases the driving force for the transduction current. Therefore, enhancing OHC potassium currents could potentially prevent salicylate-induced temporary hearing loss. In this study, we tested whether opening voltage-gated potassium channels using ICA-105665, a novel small molecule that opens KCNQ2/3 and KCNQ3/5 channels, can reduce salicylate-induced hearing loss. We found that systemic application of ICA-105665 at 10 mg/kg prevented the salicylate-induced amplitude reduction and threshold shift in the compound action potentials recorded at the round window of the cochlea. ICA-105665 also prevented the salicylate-induced reduction of distortion-product otoacoustic emission. These results suggest that ICA-105665 partially compensates for salicylate-induced cochlear hearing loss by enhancing KCNQ2/3 and KCNQ3/5 potassium currents and the motility of OHCs.

Indexed as

compound action potentialhearing lossKCNQotoacoustic emissionsalicylate

Identifiers

PMID25904892
PMCPMC4387930
OpenAlexW1991085514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.